SUMMARY
In 2014, Beck et_al found that 85% of patients in the dupilumab group, as compared with 35% of those in the placebo group, had a 50% reduction in the EASI score (see Supplementary Table S1). Meanwhile, more patients in the drugtreated group had a score of 0 to 1 on the IGA, comparing with those in placebo group; and pruritus scores decreased by 55.7% in the dupilumab group versus 15.1% in the placebo group (p and amp;lt; 0.001). Similar pattern could be observed in the trial conducted by Jo et_al, with totally 8 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.